FDA Modernization Act 3.0

Sponsored byRep. Carter, Earl L. "Buddy" [R-GA-1]GA· Introduced 10 avril 2025

Open on Congress.gov

Cosponsors

Actions

Amendments

Committees

—

Since introduced

Introduced

Committee

Passed Chamber

Passed Both

Enacted

Step 0 of 0

Latest action

Received in the Senate.

21 juillet 2026·2 days ago

Summary

Introduced in House · Updated 15 juillet 2026

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Timeline

18 actions

Received in the Senate.
21 juillet 2026 · IntroReferral
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.
20 juillet 2026 · Floor
On motion to suspend the rules and pass the bill Agreed to by voice vote.
20 juillet 2026 · Floor
Motion to reconsider laid on the table Agreed to without objection.
20 juillet 2026 · Floor
Mr. Guthrie moved to suspend the rules and pass the bill.
20 juillet 2026 · Floor
Considered under suspension of the rules.
20 juillet 2026 · Floor
Mr. Guthrie moved to suspend the rules and pass the bill.
20 juillet 2026 · Floor
DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
20 juillet 2026 · Floor
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
18 juin 2026 · Committee
Placed on the Union Calendar, Calendar No. 614.
18 juin 2026 · Calendars
Placed on the Union Calendar, Calendar No. 614.
18 juin 2026 · Calendars
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
18 juin 2026 · Committee
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
18 juin 2026 · Committee
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
18 juin 2026 · Committee
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
18 juin 2026 · Committee
Committee Consideration and Mark-up Session Held
21 mai 2026 · Committee
Committee Consideration and Mark-up Session Held
21 mai 2026 · Committee
Committee Consideration and Mark-up Session Held
21 mai 2026 · Committee
Committee Consideration and Mark-up Session Held
21 mai 2026 · Committee
Ordered to be Reported by the Yeas and Nays: 44 - 0.
21 mai 2026 · Committee

Sponsorship

41 cosponsors

Sponsor

Rep. Carter, Earl L. "Buddy" [R-GA-1]GA

Cosponsors

Democrat2151%
Republican2049%

Democrat:Rep. Thanedar, Shri [D-MI-13]MI
Republican:Rep. Langworthy, Nicholas A. [R-NY-23]NY
Republican:Rep. Kim, Young [R-CA-40]CA
Democrat:Rep. Johnson, Julie [D-TX-32]TX
Republican:Rep. Kean, Thomas H. [R-NJ-7]NJ
Democrat:Rep. Krishnamoorthi, Raja [D-IL-8]IL
Democrat:Rep. Neguse, Joe [D-CO-2]CO
Republican:Rep. Weber, Randy K. Sr. [R-TX-14]TX
Republican:Rep. Lawler, Michael [R-NY-17]NY
Democrat:Rep. Pocan, Mark [D-WI-2]WI
Democrat:Rep. Vindman, Eugene Simon [D-VA-7]VA
Republican:Rep. Calvert, Ken [R-CA-41]CA
Republican:Rep. Lee, Laurel M. [R-FL-15]FL
Republican:Rep. Fitzgerald, Scott [R-WI-5]WI
Republican:Rep. Bilirakis, Gus M. [R-FL-12]FL
Democrat:Rep. Harder, Josh [D-CA-9]CA
Republican:Rep. Valadao, David G. [R-CA-22]CA
Democrat:Rep. Frankel, Lois [D-FL-22]FL
Republican:Rep. Salazar, Maria Elvira [R-FL-27]FL
Democrat:Del. Norton, Eleanor Holmes [D-DC-At Large]DC
Republican:Rep. Tenney, Claudia [R-NY-24]NY
Republican:Rep. Smith, Christopher H. [R-NJ-4]NJ
Democrat:Rep. Lieu, Ted [D-CA-36]CA
Democrat:Rep. Crow, Jason [D-CO-6]CO
Democrat:Rep. Gottheimer, Josh [D-NJ-5]NJ
Republican:Rep. Obernolte, Jay [R-CA-23]CA
Democrat:Rep. Chu, Judy [D-CA-28]CA
Democrat:Rep. Goldman, Daniel S. [D-NY-10]NY
Democrat:Rep. Soto, Darren [D-FL-9]FL
Democrat:Rep. Scholten, Hillary J. [D-MI-3]MI
Republican:Rep. Carey, Mike [R-OH-15]OH
Republican:Rep. Fitzpatrick, Brian K. [R-PA-1]PA
Republican:Rep. Malliotakis, Nicole [R-NY-11]NY
Republican:Rep. Crenshaw, Dan [R-TX-2]TX
Democrat:Rep. Nadler, Jerrold [D-NY-12]NY
Democrat:Rep. Doggett, Lloyd [D-TX-37]TX
Republican:Rep. Buchanan, Vern [R-FL-16]FL
Democrat:Rep. DeLauro, Rosa L. [D-CT-3]CT
Democrat:Rep. Barragán, Nanette Diaz [D-CA-44]CA
Democrat:Rep. Carter, Troy A. [D-LA-2]LA
Republican:Rep. Harshbarger, Diana [R-TN-1]TN

Classification

Policy area

Health

Legislative subjects

Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationMedical researchResearch administration and funding

Committees

Energy and Commerce Committee
House · Standing
- Referred To10 Apr 2025
- Markup By21 May 2026
- Reported By18 Jun 2026
- Health Subcommittee
  - Referred to10 Apr 2026
  - Markup by13 May 2026
  - Reported by13 May 2026

Reports

H. Rept. 119-706

Cosponsor momentum

Cumulative over time

Track FDA Modernization Act 3.0 as it moves through Congress